Literature DB >> 7919339

Lymphocyte depletion during treatment with intensive chemotherapy for cancer.

C L Mackall1, T A Fleisher, M R Brown, I T Magrath, A T Shad, M E Horowitz, L H Wexler, M A Adde, L L McClure, R E Gress.   

Abstract

Recently we have observed an increased incidence of opportunistic infections in patients treated with intensive chemotherapy for cancer. Because T-cell depletion is associated with similar clinical events in human immunodeficiency virus infection and after bone marrow transplantation, we have analyzed peripheral blood lymphocyte populations in a series of patients during treatment with intensive chemotherapy for cancer. Although neutrophil, monocyte, and platelet numbers consistently recovered to greater than 50% of pretreatment values after each sequential cycle of therapy, lymphocyte numbers did not recover within the same time period. B cells decreased rapidly from a mean value of 149 +/- 46/mm3 before chemotherapy to 4 +/- 1/mm3 during chemotherapy (P = .01). CD4+ T cells decreased from a mean of 588 +/- 76/mm3 before chemotherapy to 105 +/- 28/mm3 during chemotherapy (P = .0002) and CD8+ T cells decreased from a mean of 382 +/- 41/mm3 before chemotherapy to 150 +/- 46/mm3 during chemotherapy (P = .0009). Natural killer cell numbers did not show significant declines (171 +/- 30/mm3 before, 114 +/- 24/mm3 during, P = .19). Based on the history of opportunistic complications in patients with other disorders who display similar degrees of CD4+ T-cell lymphopenia and preliminary observations in this population, immune incompetence could surface as a dose-limiting toxicity for highly dose-intensive chemotherapy regimens.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7919339

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  95 in total

Review 1.  Drug-induced lymphopenia: focus on CD4+ and CD8+ cells.

Authors:  P Gergely
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

2.  Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.

Authors:  Rachel B Salit; Daniel H Fowler; Wyndham H Wilson; Robert M Dean; Steven Z Pavletic; Kieron Dunleavy; Frances Hakim; Terry J Fry; Seth M Steinberg; Thomas E Hughes; Jeanne Odom; Kelly Bryant; Ronald E Gress; Michael R Bishop
Journal:  J Clin Oncol       Date:  2012-02-06       Impact factor: 44.544

Review 3.  The long road to the thymus: the generation, mobilization, and circulation of T-cell progenitors in mouse and man.

Authors:  Daniel A Zlotoff; Benjamin A Schwarz; Avinash Bhandoola
Journal:  Semin Immunopathol       Date:  2008-10-17       Impact factor: 9.623

Review 4.  Strategies for reconstituting and boosting T cell-based immunity following haematopoietic stem cell transplantation: pre-clinical and clinical approaches.

Authors:  Ann P Chidgey; Natalie Seach; Jarrod Dudakov; Maree V Hammett; Richard L Boyd
Journal:  Semin Immunopathol       Date:  2008-11-04       Impact factor: 9.623

5.  Disseminated adenovirus infection in cancer patients presenting with focal pulmonary consolidation.

Authors:  Yeon Joo Lee; Paola Palomino-Guilen; N Esther Babady; Daryl M Lamson; Kirsten St George; Yi-Wei Tang; Genovefa A Papanicolaou
Journal:  J Clin Microbiol       Date:  2013-10-16       Impact factor: 5.948

6.  Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization.

Authors:  Dorothea Evers; Jaap Jan Zwaginga; Janneke Tijmensen; Rutger A Middelburg; Masja de Haas; Karen M K de Vooght; Daan van de Kerkhof; Otto Visser; Nathalie C V Péquériaux; Francisca Hudig; Johanna G van der Bom
Journal:  Haematologica       Date:  2016-09-15       Impact factor: 9.941

7.  Perspective on potential clinical applications of recombinant human interleukin-7.

Authors:  Claude Sportès; Ronald E Gress; Crystal L Mackall
Journal:  Ann N Y Acad Sci       Date:  2009-12       Impact factor: 5.691

8.  AIDS, T cells, chemotherapy: HAART-breaking?

Authors:  Richard F Little
Journal:  Blood       Date:  2008-04-15       Impact factor: 22.113

9.  Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma.

Authors:  Anthony R Cillo; Amrita Krishnan; Ronald T Mitsuyasu; Deborah K McMahon; Shirley Li; John J Rossi; John A Zaia; John W Mellors
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

Review 10.  Modulating T-cell homeostasis with IL-7: preclinical and clinical studies.

Authors:  C M Capitini; A A Chisti; C L Mackall
Journal:  J Intern Med       Date:  2009-08       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.